Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Codexis Rejiggers Its Deal With Shell

by Ann M. Thayer
July 23, 2012 | A version of this story appeared in Volume 90, Issue 30

Codexis is renegotiating its collaboration with Shell to allow it to develop and sell cellulase enzymes in the biofuels area, except in Brazil. Currently, only Shell can commercialize the enzymes for biofuels, while Codexis can sell them for other applications. In addition, the partners have agreed that as of Aug. 31, Shell can choose to stop funding between 13 and 48 full-time equivalent employees (FTEs) with only one day’s notice, instead of 90 days currently. If that happens, Codexis anticipates taking cost-cutting steps. As of May 10, Shell supports 116 FTEs at Codexis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.